Brivaracetam

證據等級: L5

預測適應症: 10 個

Brivaracetam: From Focal Onset Seizures to Visual Epilepsy

One-Sentence Summary

Brivaracetam (BRV) is a third-generation antiseizure medication approved for focal onset seizures, acting as a highly selective, high-affinity synaptic vesicle protein 2A (SV2A) ligand with superior brain penetration compared to its predecessor levetiracetam. The TxGNN model assigns its highest score (99.51%) to Visual Epilepsy — a spectrum of seizures triggered by visual stimuli including photosensitive epilepsy — supported by indirect mechanistic evidence from photosensitivity model studies and 19 publications, but no dedicated clinical trials in this specific subtype. Importantly, the second-ranked prediction, Status Epilepticus, carries substantially stronger clinical evidence (Evidence Level L2, “Proceed with Guardrails”) backed by 2 completed clinical trials and 20 publications, and should be considered the primary actionable finding in this report.

Quick Overview

Item	Content
Original Indication	Focal onset seizures (adjunctive and monotherapy)
Predicted New Indication	Visual Epilepsy
TxGNN Prediction Score	99.51%
Evidence Level	L3
Denmark Market Status	Not found in Danish register
Number of Marketing Authorisations	0 (national register)
Recommended Decision	Hold (Research Question)

Why Is This Prediction Reasonable?

Brivaracetam is a propyl analog of levetiracetam and a selective, high-affinity SV2A ligand. SV2A is a synaptic vesicle glycoprotein involved in regulating neurotransmitter release — by binding this target, BRV modulates vesicle recycling and reduces the probability of excessive, synchronised neuronal firing. Compared to levetiracetam, BRV binds SV2A with 15–30 times greater affinity and penetrates the blood-brain barrier more rapidly due to its greater lipophilicity, giving it a faster onset of action. In addition to SV2A binding, BRV shows secondary activity on voltage-gated sodium channels, broadening its antiseizure profile.

Visual epilepsy encompasses seizure syndromes in which attacks are triggered by visual stimuli: flickering light (photosensitive epilepsy), geometric patterns, television screens, and other visual inputs. The primary pathophysiology involves hyperexcitability of the occipital visual cortex with rapid downstream propagation. BRV’s SV2A target is broadly expressed across cortical regions including the occipital cortex, providing a direct mechanistic basis for its potential to dampen visually-triggered cortical over-activation.

The biological rationale is further supported by early clinical evidence: a randomised double-blind crossover study (PMID 32949370) demonstrated that BRV suppresses photoparoxysmal EEG responses (PPRs) in photosensitive epilepsy patients more rapidly than levetiracetam, providing proof-of-principle for BRV activity in visually-induced seizures. A 2007 photosensitivity model study (PMID 17785672) likewise confirmed BRV’s efficacy in this model, which is considered a validated human proof-of-concept paradigm for antiseizure drug development. The existing literature in this evidence pack, although primarily addressing focal epilepsy more broadly, collectively establishes BRV’s SV2A-mediated cortical seizure suppression — a mechanism directly applicable to visual epilepsy.

Clinical Trial Evidence

Currently no clinical trials dedicated to visual epilepsy or photosensitive epilepsy are registered for brivaracetam.

The photosensitivity model (PPR suppression using intermittent photic stimulation) has been used in early-phase BRV development as a surrogate proof-of-concept endpoint, but these studies are classified under the broader photosensitivity/audiogenic evidence base rather than as formal “visual epilepsy” trials.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
31937513	2020	Pooled Analysis of RCTs	Epilepsy & Behavior	In-depth pooled safety analysis of adjunctive BRV across multiple RCTs for focal seizures; established favourable tolerability versus placebo with low rates of psychiatric adverse events
38576178	2024	Phase III RCT	Epilepsia Open	Phase III double-blind placebo-controlled trial of adjunctive BRV in adult Asian patients with focal-onset seizures; confirmed efficacy and safety across Asian populations, supporting broad applicability
26165169	2015	Meta-analysis	Expert Opinion on Pharmacotherapy	Meta-analysis of BRV at 50–200 mg/day versus placebo as adjunctive therapy; dose-dependent seizure reduction confirmed, with 50 mg/day as a clinically meaningful starting dose
37483441	2023	Systematic Review + Meta-analysis	Frontiers in Neurology	Safety and efficacy of BRV in paediatric epilepsy; positive ≥50% responder rates with acceptable adverse event rates across age groups
39664134	2024	Systematic Review	Cureus	Systematic review of BRV’s current role in adults and children with epilepsy; supports BRV as a valuable option across multiple seizure types, including where levetiracetam fails
40568060	2025	Comprehensive Review	Journal of Epilepsy Research	Synthesises BRV pharmacology, clinical trial data, and real-world evidence; highlights rapid BBB penetration, selective SV2A binding, and favourable pharmacokinetics as key advantages
38811492	2024	Narrative Review	Advances in Therapy	Reviews BRV preclinical development and clinical profile; documents 15–30-fold SV2A affinity advantage over levetiracetam and its mechanistic rationale across epilepsy subtypes
31195850	2019	Clinical Review / Trial Analysis	Expert Review of Neurotherapeutics	Detailed analysis of BRV efficacy and safety in focal epilepsy; comparison with levetiracetam including brain permeability and clinical trial responder rates
38970892	2024	Prospective Observational	Epilepsy & Behavior	EXPERIENCE pooled analysis (Australia, Europe, USA); BRV effectiveness and tolerability in older (≥65 years) versus younger adults; ≥50% responder rates and seizure-freedom rates documented in real-world settings
32120063	2020	Mechanistic Review	Neuropharmacology	Comprehensive review of antiseizure drug mechanisms; contextualises SV2A as BRV’s primary target and discusses its role in modulating cortical hyperexcitability

Denmark Market Information

The Danish Medicines Agency (Lægemiddelstyrelsen) national register returned no marketing authorisations for brivaracetam.

Important clarification: Brivaracetam (Briviact®) holds a centralised European Medicines Agency (EMA) authorisation (EU/1/16/1082), granted in January 2016, for adjunctive treatment of partial-onset (focal) seizures in adults and adolescents aged 16 years and older. This centralised authorisation is legally valid across all EU/EEA member states, including Denmark. The absence from the national register may reflect a data gap rather than true unavailability. Healthcare professionals are advised to verify current commercial availability and reimbursement status directly with Lægemiddelstyrelsen or the UCB Denmark affiliate.

Notable Secondary Finding: Status Epilepticus (Evidence Level L2)

While visual epilepsy is the top-ranked TxGNN prediction, status epilepticus (rank 3, TxGNN score 99.40%) represents the most clinically actionable repurposing candidate with a “Proceed with Guardrails” recommendation.

Clinical Trial Evidence — Status Epilepticus

Trial Number	Phase	Status	Enrollment	Key Findings
NCT07163572	Pragmatic Comparative	Completed	152	Direct head-to-head comparison of IV brivaracetam versus IV levetiracetam in acute management of paediatric status epilepticus; highest-relevance trial for this indication
NCT07443241	Observational (N/A)	Completed	779	Retrospective registry of 779 SE patients at Marburg University Hospital (2011–2023); analyses sex-specific differences in SE aetiology, treatment (including BRV use), and outcomes

Literature Evidence — Status Epilepticus (selected highlights)

PMID	Year	Type	Journal	Key Findings
31342405	2019	Systematic Review	CNS Drugs	Systematic review of IV BRV in status epilepticus; rapid brain penetration and SV2A affinity identified as pharmacological rationale for SE use
32278203	2020	Systematic Review	Journal of the Neurological Sciences	IV BRV as alternative anticonvulsant in SE; pooled case series data summarised; notes limited controlled evidence but favourable tolerability signal
32822230	2020	Clinical Practice Guideline	Epilepsy Currents	American Epilepsy Society review of parenteral ASMs for refractory convulsive SE; BRV included among third-line options with emerging evidence
41838218	2026	Systematic Review	Journal of Neurology	Most recent systematic review of BRV for SE; characterises efficacy and safety profile from available real-world and observational data
37839249	2023	Real-World Observational	Epilepsy & Behavior	Real-world effectiveness of IV BRV as second-line SE treatment; evaluates tolerability in a clinical setting following benzodiazepine failure

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for Briviact® for complete safety information, available via the EMA product page.

Practical note for Danish clinicians: As a racetam-class drug, BRV carries a class-level risk of psychiatric adverse effects (mood disturbance, irritability, depression). Importantly, BRV has a substantially lower rate of psychiatric side effects compared to levetiracetam, which is well documented in the pooled safety literature (PMID 31937513). Key pharmacokinetic interactions include induction by rifampicin and carbamazepine (CYP2C19/CYP3A4-mediated dose reduction of BRV), and a modest increase in phenytoin exposure when co-administered.

Conclusion and Next Steps

Primary Prediction — Visual Epilepsy

Decision: Hold (Research Question)

Rationale: The TxGNN model’s highest-ranked prediction for brivaracetam is mechanistically well-founded — BRV’s SV2A-mediated suppression of occipital cortex hyperexcitability is directly relevant to visually-triggered seizures, and early photosensitivity model data provide human proof-of-concept. However, no clinical trial is registered specifically for visual epilepsy as an independent indication, and all current publications represent indirect support from the broader focal epilepsy evidence base.

To proceed, the following is needed:

A dedicated investigator-initiated or industry trial evaluating BRV in confirmed photosensitive epilepsy patients using PPR suppression as a primary endpoint
Retrieval and review of the Briviact® SmPC and EPAR for full safety, pharmacokinetic, and special population data
Subgroup analysis from existing BRV RCTs to identify and characterise patients with visually-triggered or reflex seizures
Confirmation of BRV market availability and reimbursement status in Denmark with Lægemiddelstyrelsen

Secondary Prediction — Status Epilepticus

Decision: Proceed with Guardrails

Rationale: IV brivaracetam for status epilepticus is supported by two completed clinical trials (including a 152-patient paediatric head-to-head comparison with levetiracetam), multiple systematic reviews, and real-world multicentric retrospective data. BRV’s IV formulation, rapid brain penetration, and high SV2A affinity make it pharmacologically well-suited for the acute SE setting. The evidence base is sufficient to support clinical use with appropriate monitoring, particularly as a second- or third-line agent after benzodiazepine failure or in patients with prior levetiracetam intolerance.